Small molecule-based therapy for Alzheimer’s disease: NF-κBp65 ameliorates cognitive deficits in Alzheimer’s disease patients via up regulation of its target gene, 8/June/2014, 7.56 am

Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Cobalt protoporphyrin (CoPP) improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 8/June/2015, 07.27 am
June 8, 2015
Life-span extension therapy: BMP4 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 8/June/2015, 11.00 am
June 8, 2015
Show all

A recent study from the Department of Psychiatry and Psychotherapy, Georg-August-University Goettingen, Goettingen, Germany shows that “Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease.” This study was published in the 5 Jan’13 issue of the journal EMBO Mol Medicine.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based therapy for Alzheimer’s disease: NF-κBp65  ameliorates cognitive deficits in Alzheimer’s disease patients via up regulation of its target gene

Significance: 

Given that: (1) in 2006, 26.6 million people worldwide’re afflicted by Alzheimer’s disease; (2) the number of cases diagnosed with Alzheimer’s disease may increase from 26.6 million people in 2006 to 106.4 million in 2050 worldwide; (3) Alzheimer’s disease is the forth leading cause of death in US in the elderly; (4) Alzheimer’s disease is the third most costly disease to treat only after cancer and coronary heart disease; and (5) US$80–100 billion spent in US in caring for patients diagnosed with Alzheimer’s disease, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; and (ii) a side-effect-free natural product-based drug.

This study suggests, for the first time, that NF-κBp65, by increasing the expression of its target gene, it may decrease the expression of HDAC6. Thereby, it may ameliorate cognitive deficits in Alzheimer’s disease patients. Thus, pharmacological formulations encompassing “NF-κBp65 activators” may be used to improve cognitive deficits in Alzheimer’s disease patients.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Small molecule-based therapy for Alzheimer’s disease: NF-κBp65  ameliorates cognitive deficits in Alzheimer’s disease patients via up regulation of its target gene, 8/June/2014,  7.56 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How  NF-κBp65  decreases HDAC6 expression

Comments are closed.